Latest News & Features
Refine Search
Europe
Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US. 10 October 2024
Europe
Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen. 9 October 2024
Europe
A UK court upholds the patent for Astellas Pharma's life-extending prostate cancer treatment | Judgment dismisses attempts by Accord Healthcare, Sandoz, and Teva to invalidate the patent | Parallel litigation in Germany and Netherlands ongoing. 8 October 2024
Americas
Judge says use of patented protein mNeonGreen not covered by Section 271(e)(1) provision I Allele granted summary judgment in patent infringement suit. 8 October 2024
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP. 8 October 2024
Americas
Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future. 3 October 2024
Americas
German pharma giant claims Granules India’s ANDA infringes five patents I Combination therapy Jentadueto among Boehringer’s top three products in 2023 3 October 2024
Europe
Janssen Biotech denied permission to appeal invalidation of ustekinumab patent I Samsung Bioepis convinced UK court to revoke patent in July. 1 October 2024
Unified Patent Court
Having been involved in more than 30 cases at the UPC, the Bardehle Pagenberg litigator tells Marisa Woutersen why success at the game-changing court is a team effort. 1 October 2024
Europe
A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight. 27 September 2024